anselamimab

{
  "id": "MLC-T-ONC-010095",
  "term": "anselamimab",
  "field": "Oncology and biomedicine",
  "definition": "A chimeric monoclonal antibody specifically targeting human immunoglobulin light chain (LC)-related fibrils, which may potentially be used in the treatment of light chain-associated (AL) amyloidosis. Upon administration, anselamimab targets and binds to the amyloid-related, conformational epitope on LC-related fibrils. This inhibits fibrillogenesis, induces an Fc-mediated cellular inflammatory response, increases degradation and elimination of AL amyloidomas, and prevents systemic LC-associated amyloid deposits. In AL amyloidosis the amyloid fibrils are composed of immunoglobulin light chain fragments.",
  "synonyms": [
    "chimeric amyloid-reactive monoclonal antibody CAEL-101",
    "c11-1F4 mAb",
    "mAb-11-1F4"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anselamimab/"
}